Navigation Links
Lung Cancer Drug effective in extending lives

An experimental drug discovered by researchers in New Zealand and developed by the UK biotechnology company, Antisoma, is found to be effective // in extending lives of lung cancer patients by one-third.

Doctors who welcome this breakthrough state that it is the first step in the fight against the disease. Lung cancer is one of the most deadly cancers and the death rate increases every year. The rate of survival over 5 years is only 5%. The efforts to bring down the death rate have failed in the past.

A study was conducted on 70 patients affected by non-small cell lung cancer. It was found that when they were treated with the drug, not yet named and known as AS1404, they lived for 14 months on an average whereas the patients treated with chemotherapy alone lived for 8.8 months.

Efforts to find an effective treatment have failed and unlike other cancers, such as breast cancer, the death rate has not changed for more than a decade. A trial of the as yet unnamed drug, known as AS1404, in 70 patients with non-small cell lung cancer (NSCLC), the commonest kind, found they lived for 14 months on average compared with 8.8 months for those given chemotherapy alone.

According to Antisoma, this 5.2 month difference is one of the biggest ever seen in a controlled trial conducted at random in which a new agent is given along with chemotherapy to treat lung cancer. In the trial, a reduction of 27% in the risk of death was observed among those treated with AS1404 when compared to those getting only chemotherapy.

Though the difference may seem insignificant, there is a sign of real benefits from the drug. The drug belongs to a new class of compounds called vascular disrupting agents. These agents damage the blood vessels supplying the solid tumors.

The victory of phase II trial has paved way for phase III study. The result of this study will decide the licensing of the drug as safe and effective. The efficacy of AS140 4 has already been proved in the phase II trials against prostate and ovarian cancer.

Mark McKeage of the University of Auckland, one of the researchers, said: "It is great to see this large survival benefit with AS1404 in lung cancer patients. This makes me feel very optimistic as we progress into phase III testing."

Professor Alex Markham, chief executive of Cancer Research UK, said: "Our drug development team played an integral role in the early development of the drug and we're delighted with this news. We look forward to seeing how the drug performs in a much larger number of patients." Over 100 agents have been put into trials since 1982. "Over the next five years we plan to double our activity and speed up the drug development process, getting even more new drugs into clinical trials," Professor Markham said.

Over 26,000 deaths are caused by NSCLC in Britain every year.
GYT
'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... of $3,296 in property taxes a year. In some states—like New York, New ... , By contrast, many overseas retirement havens have extremely low property-tax rates, which ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
Breaking Medicine Technology: